Cartilage Oligomeric Matrix Protein (COMP) in systemic sclerosis (SSc): Role in disease severity and subclinical rheumatoid arthritis overlap

Joint Bone Spine

Volumn 79, Issue 1, 2012, Pages 51-56

  Gheita, Tamer A ^a   Hussein, Hani ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

COMP; RA overlap; Systemic sclerosis

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HUMAN; JOINT INJURY; MALE; MEDSGER SEVERITY SCORE; MODIFIED RODNAN SKIN SCORE; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; RITCHIE ARTICULAR INDEX; SCORING SYSTEM; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLUCOCORTICOIDS; GLYCOPROTEINS; HUMANS; HYPERALGESIA; JOINTS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; YOUNG ADULT;

EID: 84855683730     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.02.022     Document Type: Article

References (42)

1. Hummers L.K. The current state of biomarkers in systemic sclerosis. Curr Rheumatol Rep 2010, 12:34-39.
2. Schiopu E., Impens A.J., Phillips K. Digital ischemia in scleroderma spectrum of diseases. Int J Rheumatol 2010, 2010. [pii: 923743].
3. Baraut J., Michel L., Verrecchia F., et al. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010, 10:65-73.
4. Castro S.V., Jimenez S.A. Biomarkers in systemic sclerosis. Biomark Med 2010, 4:133-147.
5. Farina G., Lemaire R., Korn J.H., et al. Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts. Matrix Biol 2006, 25:213-222.
6. Hesselstrand R., Kassner A., Heinegård D., et al. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker. Ann Rheum Dis 2008, 67:1242-1248.
7. Kawashiri S.Y., Kawakami A., Ueki Y., et al. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab. Joint Bone Spine 2010, 77:418-420.
8. Valentini G., Cuomo G., Abignano G., et al. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) 2011, 50:317-323.
9. Mok M.Y., Lau C.S. The burden and measurement of cardiovascular disease in SSc. Nat Rev Rheumatol 2010, 6:430-434.
10. Randone S.B., Guiducci S., Cerinic M.M. Musculoskeletal involvement in systemic sclerosis. Best Pract Res Clin Rheumatol 2008, 22:339-350.
11. Chitale S., Ciapetti A., Hodgson R., et al. Magnetic resonance imaging and musculoskeletal ultrasonography detect and characterize covert inflammatory arthropathy in systemic sclerosis patients with arthralgia. Rheumatology (Oxford) 2010, 49:2357-2361.
12. Koutaissoff S, Vanthuyne M, Smith V, et al. Hand radiological damage in systemic sclerosis: comparison with a Control Group and clinical and functional correlations. Semin Arthritis Rheum 2010 Sep 21 [Epub ahead of print].
13. Marrone M., Chialà A., Tampoia M., et al. Prevalence of anti-CCP antibodies in systemic sclerosis. Reumatismo 2007, 59:20-24.
14. Avouac J., Walker U., Tyndall A., et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010, 37:1488-1501.
15. Szücs G., Szekanecz Z., Zilahi E., et al. Systemic sclerosis-rheumatoid arthritis overlap syndrome: a unique combination of features suggests a distinct genetic, serological and clinical entity. Rheumatology (Oxford) 2007, 46:989-993.
16. Malesci D., La Montagna G., Valentini G. The arthropathy of systemic sclerosis. Reumatismo 2005, 57:232-237.
17. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
18. Leroy E.C., Black C., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
19. Aletaha D., Neogi T., Silman A.J., et al. 2010 Rheumatoid Arthritis Classification Criteria: an American College Of Rheumatology/European League against rheumatism. Arhtritis Rheum 2010, 62:2569-2581.
20. Alarcon-Segovia D., Cardiel M.H. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989, 16:328-334.
21. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
22. Tanimoto K., Nakano K., Kano S., et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995, 22:668-674.
23. Clements P., Lachenbruch P., Seibold J., et al. Inter- and intraobserver variability of total skin thickness score (modified Rodan TSS) in systemic sclerosis. J Rheumatol 1995, 22:1281-1285.
24. Medsger T.A., Bombardieri S., Czirjak L., et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003, 21:S42-S46.
25. Ritchie D.M., Boyle J.A., McInnes J.M., et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968, 37:393-406.
26. Farina G., Lemaire R., Pancari P., et al. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta. Ann Rheum Dis 2009, 68:435-441.
27. Bertazzi G.R., de Toledo R.A., de Godoy M.F., et al. Skin manifestation in systemic sclerosis. Acta Reumatol Port 2010, 35:184-190.
28. Ostojić P., Damjanov N. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin Rheumatol 2006, 25:453-457.
29. Farina G., Lafyatis D., Lemaire R., et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010, 62:580-588.
30. Bérezné A., Seror R., Morell-Dubois S., et al. Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers. Arthritis Care Res (Hoboken) 2011, 63:277-285.
31. Ueda-Hayakawa I., Hasegawa M., Kumada S., et al. Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology (Oxford) 2010, 49:2135-2139.
32. Morita Y., Muro Y., Sugiura K., et al. Anti-cyclic citrullinated peptide antibody in systemic sclerosis. Clin Exp Rheumatol 2008, 26:542-547.
33. Santiago M., Baron M., Miyachi K., et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008, 27:77-83.
34. Ingegnoli F., Galbiati V., Zeni S., et al. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol 2007, 26:510-514.
35. Horiki T., Moriuchi J., Takaya M., et al. The coexistence of systemic sclerosis and rheumatoid arthritis in five patients. Arthritis Rheum 1996, 39:152-156.
36. Generini S., Steiner G., Miniati I., et al. Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. Rheumatology (Oxford) 2009, 48:920-925.
37. Allali F., Tahiri L., Senjari A., et al. Erosive arthropathy in systemic sclerosis. BMC Public Health 2007, 22:260.
38. Gulati D., Kushner I., File E., et al. Primary Sjogren's syndrome with anticentromere antibodies--a clinically distinct subset. Clin Rheumatol 2010, 29:789-791.
39. Swaminathan S., Goldblatt F., Dugar M., et al. Prevalence of sicca symptoms in a South Australian cohort with systemic sclerosis. Intern Med J 2008, 38:897-903.
40. Avouac J., Sordet C., Depinay C., et al. Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum 2006, 54:2243-2249.
41. Johnson S.R., Glaman D.D., Schentag C.T., et al. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006, 33:1117-1122.
42. Crnkic M., Månsson B., Larsson L., et al. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 2003, 5:R181-R185.